Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E15.12 EPS (ttm)4.16 Insider Own0.40% Shs Outstand1.29B Perf Week-5.07%
Market Cap80.95B Forward P/E9.08 EPS next Y6.93 Insider Trans-2.69% Shs Float1.27B Perf Month-2.55%
Income5.46B PEG- EPS next Q1.61 Inst Own82.70% Short Float0.90% Perf Quarter-8.30%
Sales22.13B P/S3.66 EPS this Y-45.60% Inst Trans0.19% Short Ratio1.57 Perf Half Y-17.51%
Book/sh16.63 P/B3.79 EPS next Y4.67% ROA8.40% Target Price80.43 Perf Year-16.82%
Cash/sh23.40 P/C2.69 EPS next 5Y-3.60% ROE25.20% 52W Range60.32 - 79.61 Perf YTD0.64%
Dividend2.52 P/FCF17.97 EPS past 5Y18.10% ROI12.30% 52W High-20.93% Beta1.19
Dividend %4.00% Quick Ratio3.30 Sales past 5Y14.60% Gross Margin78.10% 52W Low4.36% ATR1.41
Employees11000 Current Ratio3.40 Sales Q/Q-2.60% Oper. Margin37.60% RSI (14)36.39 Volatility2.71% 1.98%
OptionableYes Debt/Eq1.28 EPS Q/Q-98.90% Profit Margin24.70% Rel Volume1.60 Prev Close63.25
ShortableYes LT Debt/Eq1.15 EarningsMay 02 AMC Payout54.30% Avg Volume7.21M Price62.95
Recom2.20 SMA20-3.74% SMA50-3.91% SMA200-10.55% Volume11,494,405 Change-0.47%
Apr-10-19Upgrade UBS Neutral → Buy $75 → $77
Feb-12-19Downgrade Wells Fargo Outperform → Market Perform $95 → $68
Feb-12-19Downgrade Citigroup Buy → Neutral $100 → $75
Jan-03-19Upgrade Oppenheimer Perform → Outperform $85
Oct-26-18Reiterated Barclays Overweight $90 → $95
Oct-26-18Downgrade Piper Jaffray Overweight → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $87
Jul-26-18Downgrade Robert W. Baird Outperform → Neutral $79
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Dec-20-17Downgrade Credit Suisse Outperform → Neutral
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Apr-20-19 10:36PM  Stocks That Fell to 3-Year Lows in the Week of April 19 GuruFocus.com
Apr-19-19 02:48PM  Top Gene-Sequencing Stocks for 2019 Motley Fool
Apr-18-19 11:12PM  The Top 10 Biotechnology Companies (JNJ, ROG.VX) Investopedia
04:05PM  Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 2019 Business Wire
10:59AM  Can Q1 Earnings Lift Healthcare ETFs Higher? Zacks
09:17AM  Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline Zacks
07:30AM  Jim Cramer Shares His Thoughts On AMD, Gilead, Nvidia And More Benzinga
Apr-17-19 11:03AM  Gilead Collaborates With Insitro to Develop NASH Therapies Zacks
07:48AM  Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal Zacks
Apr-16-19 04:23PM  How This Biotech Giant Is Using Machine Learning In Liver Disease Investor's Business Daily
10:52AM  Why Amgen Stock Could Break Out to New Highs InvestorPlace
09:51AM  Gilead teams with startup to turn machine learning on fatty liver disease American City Business Journals
07:00AM  Gilead teams up with insitro for experimental NASH treatments Reuters
07:00AM  Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis Business Wire
Apr-15-19 05:50PM  Gilead Sciences (GILD) Gains As Market Dips: What You Should Know Zacks
04:26PM  Gilead to Collaborate with Novo Nordisk for NASH Treatment Zacks
06:58AM  Goldman Sachs's 20 best stocks to invest in now Yahoo Finance
Apr-14-19 09:16AM  Better Buy: Gilead Sciences vs. Biogen Motley Fool
Apr-13-19 12:28PM  Better Buy: Amgen vs. Gilead Sciences Motley Fool
Apr-12-19 07:20AM  Gilead Sciences Teams With Novo Nordisk for Trials of Liver Disease Drugs TheStreet.com
07:06AM  8 Stocks May Jump on Takeovers as Market Nears Peak Investopedia
04:57AM  Novo Nordisk and Gilead team up to test fatty liver disease treatment Reuters
04:00AM  Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH Business Wire
Apr-11-19 10:03AM  Intercept Reports Additional Positive Data From NASH Study Zacks
09:18AM  Gilead Presents New Data on Viral Hepatitis at the International Liver Congress 2019 Business Wire
07:48AM  The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug Benzinga
02:00AM  Gilead Presents New Data in Nonalcoholic Steatohepatitis (NASH) at the International Liver Congress 2019 Business Wire
Apr-10-19 12:29PM  Gilead Sciences 2019 Earnings Could Be Strong, but Watch Out for the First Quarter, Analyst Says Barrons.com
11:25AM  Gilead stock upgraded to buy from neutral at UBS MarketWatch
11:17AM  UBS Upgrades Gilead, Sees EPS Upside In 2019 Benzinga
09:20AM  Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More Zacks
08:54AM  If You Had Bought Gilead Sciences (NASDAQ:GILD) Stock Three Years Ago, You'd Be Sitting On A 32% Loss, Today Simply Wall St.
Apr-09-19 12:00PM  Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases Business Wire
08:02AM  Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients Zacks
07:46AM  Why Galapagos NV Stock Bolted Higher in March Motley Fool
07:16AM  3 Dividend Stocks Perfect for Retirees Motley Fool
06:00AM  Gilead- Pipeline Promise and a Sector-High Yield MoneyShow
Apr-08-19 05:50PM  Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks
05:25PM  Gilead Files sNDA for Label Expansion of HIV Therapy Descovy Zacks
04:51PM  GSK wins U.S. nod for two-drug HIV combination Reuters
04:26AM  GSK two-drug/one-pill HIV treatment given FDA approval in US Financial Times
Apr-07-19 09:00AM  Where Will Gilead Sciences Be in 5 Years? Motley Fool
Apr-05-19 08:30AM  Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis Business Wire
Apr-02-19 07:44PM  Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences Motley Fool
09:56AM  Elon Musks CEO pay-to-worker ratio is the highest ever recorded how it compares at other tech companies American City Business Journals
Apr-01-19 05:50PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
09:15AM  2 Incredibly Cheap Pharma Stocks to Buy Now Motley Fool
Mar-29-19 05:24PM  Can These Biotech Stocks Take On Arthritis Powerhouse AbbVie? Investor's Business Daily
03:23PM  Wall Street is buzzing about Gileads rheumatoid arthritis drug. Heres why MarketWatch
12:12PM  Can These Biotech Stocks Take On Arthritis Powerhouse AbbVie? Investor's Business Daily
11:31AM  Why Galapagos Stock Is Crushing It Today Motley Fool
11:06AM  Galapagos Soars After Rheumatoid Arthritis Drug Meets Primary Endpoint TheStreet.com
10:56AM  Gilead Sciences and Galapagos Stock Are Rising on Upbeat Trial Data Barrons.com
07:42AM  The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead Benzinga
04:06AM  Stocks - Wells Fargo, Gilead and Blackberry Rise in Pre-market Investing.com
Mar-28-19 05:09PM  GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) GlobeNewswire
05:04PM  Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients Business Wire
05:03PM  Gilead and Galapagos Announce Filgotinib Meets Primary and Key Secondary Endpoints in the Phase 3 FINCH 1 Rheumatoid Arthritis Study Business Wire
05:02PM  GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS GlobeNewswire
05:02PM  Gilead and Galapagos Report Updated Safety Information for Filgotinib in Rheumatoid Arthritis (RA) Business Wire
05:01PM  GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY GlobeNewswire
05:00AM  Gilead Launches HepConnect Initiative to Reduce Hepatitis C Infections in Greater Appalachia Business Wire
Mar-27-19 03:40PM  3 Top Dividend Stocks to Add to Your Watchlist Motley Fool
10:55AM  Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL Zacks
08:48AM  Were Hedge Funds Right About Souring On Gilead Sciences, Inc. (GILD)? Insider Monkey
06:06AM  Gilead to Present New Data From Multiple Liver Disease Research and Development Programs at The International Liver Congress 2019 Business Wire
Mar-26-19 08:30AM  Japans Ministry of Health, Labour and Welfare Approves Gileads Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection Business Wire
Mar-25-19 05:50PM  Gilead Sciences (GILD) Gains As Market Dips: What You Should Know Zacks
Mar-24-19 09:00AM  Why 1 Top Analyst Thinks Gilead Sciences Will Soar More Than 25% Motley Fool
Mar-22-19 05:43PM  Conatus (CNAT) Declines on Failure of NASH Fibrosis Study Zacks
10:20AM  Biogen Stock Fell Too Far on Unfortunate News InvestorPlace
Mar-21-19 07:56AM  Does Recent Weakness in AbbVie Stock Make It a Buy? 3 Pros, 3 Cons InvestorPlace
Mar-19-19 05:45PM  Gilead Sciences (GILD) Gains As Market Dips: What You Should Know Zacks
Mar-18-19 04:09PM  New shareholder challenge to Gilead: What are you doing with billions in tax savings? American City Business Journals
12:26PM  Gilead Sciences Increased Some Drug Prices. Why Thats Good News and Bad News for the Stock. Barrons.com
10:45AM  YETI, Gilead, Dick's, FedEx and Amazon highlighted as Zacks Bull and Bear of the Day Zacks
09:42AM  With parting gifts, Gilead CEO's compensation soared American City Business Journals
06:23AM  Bear of the Day: Gilead Sciences (GILD) Zacks
Mar-17-19 07:31AM  Better Buy: Amgen vs. Gilead Sciences Motley Fool
Mar-14-19 11:13AM  Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up Zacks
Mar-13-19 05:45PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
Mar-09-19 06:00AM  3 Top Biotech Stocks to Buy in March Motley Fool
Mar-08-19 06:15PM  Stocks That Fell to 3-Year Lows in the Week of March 8 GuruFocus.com
03:46PM  Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy Zacks
10:20AM  Dont Abandon Gilead Stock After Weak Q4 Results InvestorPlace
Mar-07-19 05:30PM  Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies Business Wire
01:53PM  10 Top Pot Stocks 2019 Has to Offer InvestorPlace
01:50PM  Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy Zacks
06:03AM  2 Biotech Stocks With Major Incoming Catalysts Motley Fool
01:45AM  [$$] Monthly jab for HIV treatment passes late-stage trials Financial Times
Mar-06-19 05:30PM  Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women Business Wire
05:30PM  Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance Business Wire
02:10PM  Gilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy® vs. Once-Daily Truvada® for Prevention of HIV Infection Business Wire
11:23AM  Can Gilead Sciences Return to Winning Ways? GuruFocus.com
09:50AM  As new Gilead CEO enters, cancer chief exits American City Business Journals
09:30AM  Why Is Gilead (GILD) Down 4.9% Since Last Earnings Report? Zacks
08:16AM  3 Big Pharmas Trying to Pop the Rebate Bubble Motley Fool
Mar-05-19 06:57PM  U.S. FDA chief tough on e-cigs steps down in surprise resignation Reuters
04:30PM  Gilead Announces Senior Management Change Business Wire
04:05PM  Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 12 Business Wire
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Scholar Rock Holding Corporation; Tango Therapeutics; National Cancer Institute; Pfizer, Inc.; Sangamo Therapeutics, Inc.; Gadeta B.V.; HiFiBiO Therapeutics; and Agenus Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cogan John FrancisDirectorApr 17Option Exercise22.022,70059,44157,560Apr 18 07:04 PM
Cogan John FrancisDirectorApr 17Sale64.232,700173,42454,860Apr 18 07:04 PM
Cogan John FrancisDirectorApr 10Option Exercise22.022,70059,44157,560Apr 12 06:28 PM
Cogan John FrancisDirectorApr 10Sale67.232,700181,52154,860Apr 12 06:28 PM
Cogan John FrancisDirectorApr 03Option Exercise22.022,70059,44157,560Apr 04 07:31 PM
Cogan John FrancisDirectorApr 03Sale66.742,700180,19854,860Apr 04 07:31 PM
Whitley Richard JamesDirectorApr 01Option Exercise22.029,534209,89134,669Apr 02 08:10 PM
Whitley Richard JamesDirectorApr 01Sale65.489,534624,25525,135Apr 02 08:10 PM
Cogan John FrancisDirectorMar 27Option Exercise22.022,70059,44157,560Mar 28 06:09 PM
Cogan John FrancisDirectorMar 27Sale64.142,700173,17854,860Mar 28 06:09 PM
Cogan John FrancisDirectorMar 20Option Exercise22.022,70059,44157,560Mar 21 07:08 PM
Cogan John FrancisDirectorMar 20Sale65.072,700175,68954,860Mar 21 07:08 PM
WILSON GAYLE EDirectorFeb 19Option Exercise0.0019,0680143,567Feb 20 08:06 PM
WILSON GAYLE EDirectorFeb 19Sale67.0819,0681,279,074124,499Feb 20 08:06 PM
MARTIN JOHN CDirectorDec 03Option Exercise23.6050,0001,180,0002,927,762Dec 04 08:02 PM
MARTIN JOHN CDirectorDec 03Sale71.2050,0003,560,1782,877,762Dec 04 08:02 PM
MILLIGAN JOHN FPresident and CEONov 27Option Exercise23.60280,0006,608,0001,574,306Nov 29 08:42 PM
MARTIN JOHN CDirectorNov 01Option Exercise23.6050,0001,180,0003,067,762Nov 05 07:45 PM
MARTIN JOHN CDirectorNov 01Sale69.5550,0003,477,6173,017,762Nov 05 07:45 PM
MARTIN JOHN CDirectorOct 01Option Exercise23.6050,0001,180,0003,067,762Oct 03 05:45 PM
MARTIN JOHN CDirectorOct 01Sale78.0450,0003,902,2103,017,762Oct 03 05:45 PM
MARTIN JOHN CDirectorSep 04Option Exercise23.6050,0001,180,0003,067,762Sep 06 05:24 PM
MARTIN JOHN CDirectorSep 04Sale74.1650,0003,708,0343,017,762Sep 06 05:24 PM
MARTIN JOHN CDirectorAug 01Option Exercise23.6050,0001,180,0003,067,762Aug 03 04:41 PM
MARTIN JOHN CDirectorAug 01Sale77.8550,0003,892,6503,017,762Aug 03 04:41 PM
MARTIN JOHN CDirectorJul 02Option Exercise23.6050,0001,180,0003,067,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJul 02Sale70.8150,0003,540,2823,017,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJun 01Option Exercise23.6050,0001,180,0003,067,762Jun 05 07:34 PM
MARTIN JOHN CDirectorJun 01Sale68.1350,0003,406,4953,017,762Jun 05 07:34 PM
MILLIGAN JOHN FPresident and CEOMay 04Option Exercise27.0780,0002,165,6001,294,306May 08 06:29 PM
Cogan John FrancisDirectorMay 04Option Exercise26.625,836155,32558,455May 08 01:59 PM
Cogan John FrancisDirectorMay 04Sale65.095,836379,88552,619May 08 01:59 PM
MARTIN JOHN CDirectorMay 01Option Exercise23.6050,0001,180,0003,067,762May 03 01:07 PM
MARTIN JOHN CDirectorMay 01Sale72.1950,0003,609,6603,017,762May 03 01:07 PM
Cogan John FrancisDirectorApr 27Option Exercise26.625,833155,24558,452Apr 30 05:39 PM
Cogan John FrancisDirectorApr 27Sale73.915,833431,11752,619Apr 30 05:39 PM